PE20231097A1 - Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso - Google Patents

Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso

Info

Publication number
PE20231097A1
PE20231097A1 PE2022000849A PE2022000849A PE20231097A1 PE 20231097 A1 PE20231097 A1 PE 20231097A1 PE 2022000849 A PE2022000849 A PE 2022000849A PE 2022000849 A PE2022000849 A PE 2022000849A PE 20231097 A1 PE20231097 A1 PE 20231097A1
Authority
PE
Peru
Prior art keywords
delta
4alkoxy
methods
heterocyclic compounds
haloc1
Prior art date
Application number
PE2022000849A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer R Allen
Michela Beltrani
Matthew P Bourbeau
Teodora P Damyanova
Iain Lingard
Ana E Minatti
Paolo Vincetti
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20231097A1 publication Critical patent/PE20231097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2022000849A 2019-11-25 2020-11-24 Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso PE20231097A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
PE20231097A1 true PE20231097A1 (es) 2023-07-18

Family

ID=73855555

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000849A PE20231097A1 (es) 2019-11-25 2020-11-24 Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso

Country Status (21)

Country Link
US (3) US11512097B2 (OSRAM)
EP (1) EP4065223A1 (OSRAM)
JP (2) JP7254246B2 (OSRAM)
KR (2) KR20230154292A (OSRAM)
CN (2) CN118161500A (OSRAM)
AR (1) AR120556A1 (OSRAM)
AU (1) AU2020392087B2 (OSRAM)
BR (1) BR112022010054A2 (OSRAM)
CA (1) CA3162281A1 (OSRAM)
CL (2) CL2022001357A1 (OSRAM)
CO (1) CO2022008690A2 (OSRAM)
CR (1) CR20220308A (OSRAM)
IL (1) IL293191B2 (OSRAM)
JO (1) JOP20220125A1 (OSRAM)
MX (1) MX2022006281A (OSRAM)
PE (1) PE20231097A1 (OSRAM)
PH (1) PH12022551282A1 (OSRAM)
SA (1) SA522432710B1 (OSRAM)
TW (2) TWI815061B (OSRAM)
UY (1) UY38971A (OSRAM)
WO (1) WO2021108408A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CN118161500A (zh) * 2019-11-25 2024-06-11 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
EP4622648A1 (en) 2022-11-23 2025-10-01 Amgen Inc. Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
JP2641443B2 (ja) 1986-04-07 1997-08-13 クミアイ化学工業株式会社 ５Ｈ−１，３，４−チアジアゾロ〔３，２−ａ〕ピリミジン−５−オン誘導体及びこれを有効成分とする農園芸用殺菌剤
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
HK1047437B (en) 1999-10-15 2005-12-16 Neurocrine Biosciences, Inc. Gonadotropin releasing hormone receptor antagonists and their related methods of use
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
KR20070091677A (ko) 2004-12-24 2007-09-11 아스트라제네카 아베 Ｃｃｒ2ｂ 길항제로서의 헤테로시클릭 화합물
DE602006015658D1 (de) 2005-06-27 2010-09-02 Amgen Inc Entzündungshemmende arylnitrilverbindungen
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
JP2009502864A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌性の５−メチル−６−フェニルトリアゾロピリミジニルアミン
MX2008000357A (es) 2005-07-27 2008-03-07 Basf Ag 6-feniltriazolopirimidinilaminas fungicidas.
JP2009502863A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア ６−フェニル−ピラゾロピリミジン−７−イルアミン殺菌剤
WO2007044441A2 (en) 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
AU2007302245A1 (en) 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
JP2010505881A (ja) 2006-10-05 2010-02-25 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
US8173661B2 (en) 2006-11-08 2012-05-08 The Rockefeller University Alpha-IIB-beta-3 inhibitors and uses thereof
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
BRPI0806347A2 (pt) 2007-01-19 2011-09-06 Basf Se misturas fungicidas, agente fungicida, método para combater fungos nocivos fitopagênicos, semente, e, processo para preparar um agente
WO2008092836A2 (en) 2007-01-30 2008-08-07 Basf Se Method for improving plant health
BRPI0809045A2 (pt) 2007-03-23 2014-09-02 Basf Se Combinações de substância ativa, uso de combinações de substância ativa, métodos para combater fungos fitopatogênicos indesejáveis, para preparar agentes pesticidas, e para tratar sementes, e, produto de revestimento de semente
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2274308A1 (en) 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
AR075158A1 (es) 2009-01-27 2011-03-16 Takeda Pharmaceutical Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JPWO2012011592A1 (ja) 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2013177538A2 (en) 2012-05-24 2013-11-28 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
EP3041474B1 (en) 2013-09-05 2020-03-18 Genentech, Inc. Antiproliferative compounds
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
AU2015251207B2 (en) 2014-04-23 2019-08-22 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
WO2017112678A1 (en) 2015-12-21 2017-06-29 Rima Mcleod Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
CN106749271B (zh) 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
WO2018213365A1 (en) 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
AU2018331456B2 (en) 2017-09-15 2020-10-08 Chinook Therapeutics, Inc. Pyrazolopyrimidinone compounds and uses thereof
CN118161500A (zh) 2019-11-25 2024-06-11 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Also Published As

Publication number Publication date
CL2023002486A1 (es) 2024-01-12
CN114728167B (zh) 2024-03-19
CL2022001357A1 (es) 2023-03-10
IL293191B1 (en) 2025-05-01
JP7254246B2 (ja) 2023-04-07
WO2021108408A1 (en) 2021-06-03
BR112022010054A2 (pt) 2022-08-16
IL293191A (en) 2022-07-01
MX2022006281A (es) 2022-06-08
CN114728167A (zh) 2022-07-08
PH12022551282A1 (en) 2023-11-29
AU2020392087A1 (en) 2022-06-09
JOP20220125A1 (ar) 2023-01-30
US12448396B2 (en) 2025-10-21
TWI867822B (zh) 2024-12-21
TW202409042A (zh) 2024-03-01
TWI815061B (zh) 2023-09-11
IL293191B2 (en) 2025-09-01
US20210188874A1 (en) 2021-06-24
KR20220106159A (ko) 2022-07-28
US20230159560A1 (en) 2023-05-25
KR102598203B1 (ko) 2023-11-03
US11512097B2 (en) 2022-11-29
TW202132317A (zh) 2021-09-01
JP2022549739A (ja) 2022-11-28
CR20220308A (es) 2022-08-04
AR120556A1 (es) 2022-02-23
AU2020392087B2 (en) 2025-10-23
KR20230154292A (ko) 2023-11-07
CA3162281A1 (en) 2021-06-03
SA522432710B1 (ar) 2025-05-29
CN118161500A (zh) 2024-06-11
JP7698676B2 (ja) 2025-06-25
CO2022008690A2 (es) 2022-06-30
EP4065223A1 (en) 2022-10-05
JP2023078418A (ja) 2023-06-06
UY38971A (es) 2021-06-30
US20210221824A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
PE20231097A1 (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
SE0402735D0 (sv) Novel compounds
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
CL2008003786A1 (es) Compuestos derivados de 1h-pirazolo[3,4-c]piridazinilo, 1h pirazolo[3,4-b]piridinilo, ah-pirazolo[3,4-c]piridinilo e indazolilo, inhibidores no nucleosidicos de la transcriptasa reversa del vih-1(nnrti); composicion fa<rma<ceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por viv, sida o arc.
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
BR112023025599A2 (pt) Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
BR112021019629A2 (pt) Derivado de espiro que contém nitrogênio como inibidor de ret
JOP20210313A1 (ar) مشتقات حلقية غير متجانسة مندمجة
PE20201068A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CL2020002202A1 (es) Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicación del ortomixovirus para el tratamiento de la influenza
AR044275A1 (es) Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
MX2022004713A (es) Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.
BR0308309A (pt) Derivados de isoxazolina amino substituìdo e seu uso como antidepressivos
EA202191966A1 (ru) Пентациклическое гетероциклическое соединение
EA202191046A1 (ru) Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1
MX2024001751A (es) Compuestos de heteroarilo de anillo fusionado y uso de los mismos.